



Development and Evaluation of Inhalable Dry Powder Formulations

Guest Editors:

Prof. Dr. Heidi M. Mansour

Center for Translational Science,
Florida International University
(FIU), 11350 SW Village Parkway,
CTS 314, Port Saint Lucie, FL
34987, USA

hmansour@fiu.edu

Dr. Basanth Babu Eedara

Center for Translational Science,
Florida International University
(FIU), 11350 SW Village Parkway,
CTS 321, Port Saint Lucie, FL
34987, USA

beedara@fiu.edu

Deadline for manuscript
submissions:

closed (28 February 2023)

Message from the Guest Editors

Dear Colleagues,

Respiratory drug delivery is an important route for the administration of treatment and prevention of diseases of the respiratory tract (nasal and pulmonary regions), and for delivering drugs non-invasively to the central nervous system (CNS). Pulmonary drug delivery has recently gained a significant importance in the therapeutic field due to the various advantages, such as pain-free administration, targeted drug delivery with minimum systemic exposure, rapid onset of action, reduced enzymatic degradation, high drug-concentrations in the lungs, and avoidance of hepatic first-pass metabolism compared to the other conventional routes of administration. Formulations including biologicals have shown an increased stability when they are in solid-state rather than liquid formulations, making dry powder inhalers (DPIs) the more preferred formulation for pulmonary drug delivery. This Special Issue focuses on the design and development of innovative dry powder formulations as inhalation aerosols by the lung and nasal routes of administration.

Prof. Dr. Heidi M. Mansour

Dr. Basanth Babu Eedara

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Yvonne Perrie

Strathclyde Institute of Pharmacy
and Biomedical Sciences,
University of Strathclyde,
Glasgow G4 0RE, UK

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[@MDPIpharma](https://twitter.com/MDPIpharma)